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PATTERNS OF ANTIVIRAL THERAPY USE AMONG CHRONIC
HEPATITIS C PATIENTS ENROLLED IN MEDICAID
Hsu CN, Kauf TL, Lipowski E
University of Florida, Gainesville, FL, USA
OBJECTIVES: To describe medication use patterns among
patients with chronic Hepatitis C virus (HCV) infection in a
Medicaid population. METHODS: Florida Medicaid claims
from January 2000 through December 2004 were analyzed for
persons with a diagnosis of HCV infection (ICD-9 codes: 70.50
or 70.54). The date of the ﬁrst pharmacy claim for ribavirin,
interferon, peg-interferon, or peg-interferon plus ribavirin served
as the index date. To be included in the analysis, patients had to
be enrolled for 3 months prior to the index date and °Y´12
months after the index date. Patients with enrollment gaps
exceeding 3 months (cumulative) were excluded. Treatment pat-
terns assessed included: duration of treatment, number of reﬁlls,
and treatment persistency. Duration of treatment was deﬁned as
days (date of the last claim minus the index date) plus days’
supply of the last claim). Treatment was considered discontin-
ued if the number of uncovered days (based on last claim date
and days’ supply) exceeded 34. Treatment persistency was
deﬁned as days from the index date to the ﬁrst event of treat-
ment discontinuation in the treatment duration. A Kaplan-Meier
plot provided the probability of remaining persistence with drug
over time. RESULTS: Of 10,016 patients with HCV diagnosis,
1,127 antiviral therapy users met study inclusion criteria. The
majority of patients (90.9%) was treated with combination
therapy and had multiple interferon claims in the study period.
Mean duration of treatment was 7.1 (±4.33) months. 25.7% of
patients received therapy °Ü3 months; 25.9%, 3–6 months;
27.2%, 7–12 months; and 21.1%, >12 months. Mean number
of reﬁlls was 6.2 (±4.07). Median time to discontinuation was
203 days (6.8 months). CONCLUSION: Half of patients begin-
ning antiviral therapy for chronic hepatitis C discontinued 
treatment within 24 weeks. Although some patients likely dis-
continued therapy because of non-response or HCV genotype,
additional research to identify reasons for treatment discontinu-
ation is warranted.
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ANALYSES FROM ROUTINE PATIENT CARE SETTINGS FOR
CLINICAL RESEARCH PURPOSES
Ross SD, Frame D,Winterkorn A, Fahrbach K
United BioSource Corporation, Medford, MA, USA
OBJECTIVES: Comparative effectiveness research using real-
world patient data collected outside of clinical trials is expected
to increase dramatically in the coming decade as electronic
medical records (EMRs) are more widely adopted in routine
patient care settings. Retrospective analyses of such data to
answer clinical questions will be easier than ever to perform, but
with greater ease comes greater threats to validity. Our objective
here is to describe a methodology we developed to move beyond
the traditional chart review towards a way to use clinical prac-
tice data for reliable comparative effectiveness assessments.
METHODS: We recently planned and performed an analysis of
retrospective data from routine patient care settings from several
liver clinics (with varying use of clinical databases) to compare
the relative effectiveness of two commonly used treatment regi-
mens in adults with chronic HCV infection. Participating clini-
cians in Europe and the US were initially identiﬁed via
authorship of published abstracts of single center case series of
HCV patients. A project protocol was prospectively developed
to deﬁne site and patient eligibility criteria, and to provide sites
with a template for transmission of speciﬁc data elements for
analysis. Data privacy, security, and IRB issues were addressed,
and a statistical analysis plan included sample size calculations
and hierarchical linear modeling methods to adjust both site and
patient level variables concurrently. Agreement to disseminate
results regardless of ﬁndings was obtained up-front from all
investigators and the corporate sponsor. RESULTS: N/A CON-
CLUSION: A rigorous and standardized methodology is
urgently needed to advance the science of clinical effectiveness
research using real-world patient records, especially those
obtained from EMR systems. The approach described herein
could serve as a useful case in point.
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ESTIMATING THE GDP SAVED DUE TO AIDS TREATMENT
Becker RV, Munakata J
ValueMedics Research, LLC, Falls Church,VA, USA
OBJECTIVES: A recent study estimated that treatment for AIDS
saved 2.8 million life-years (Walensky, JID, June 2006). This
study attempts to estimate the economic impact of those life-
years saved on the U.S. economy. METHODS: Beginning with
1987, the number of life-years saved per patient was multiplied
by the real per capita GDP in the U.S. (base year 2000) to deter-
mine the real per capita GDP saved. These ﬁgures were then
summed for patients initiating therapy through 2003 to deter-
mine the total GDP per capita saved. This sum was also multi-
plied by the number of patients receiving treatment to determine
the total GDP saved throughout the period. The impact on the
per capita GDP for the total U.S. population was calculated by
subtracting the GDP saved from the total GDP each year and
then dividing by the total U.S. population. GDP in out-years is
estimated by the average increase in real GDP from 1987 to
2003. RESULTS: For patients initiating therapy from 1987 to
2003, the total GDP saved is $100.8 billion through 2015, or
$166,000 GDP per capita receiving treatment. The GDP saved
ranged from $289 million in 1991 to $7.6 billion in 2003. The
impact on per capita GDP for the entire U.S. population ranged
from less than $0.81 saved in 1991 to nearly $26.55 in 2003.
CONCLUSION: The impact of AIDS drug treatment on the U.S.
economy is signiﬁcant and should be considered during analysis
of the costs and beneﬁts of AIDS treatment in U.S. Further analy-
sis is needed to assess similar impact of AIDS treatment in other
countries.
PIN34
W
IT
HD
RA
W
N
